These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 9783191

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
    Takeuchi S, Yoshida K, Tosaka A, Kobayashi N, Higashi Y, Negishi T.
    Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H, Usami M, Kotake T, Koiso K, Aso Y.
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [Abstract] [Full Text] [Related]

  • 9. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
    Takeuchi S, Yoshida K, Tosaka A, Kobayashi N, Uchijima Y, Saitoh H.
    Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
    [Abstract] [Full Text] [Related]

  • 12. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T, Kawabe K.
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [Abstract] [Full Text] [Related]

  • 13. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N, Kawai K, Akaza H, Koiso K.
    Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
    [Abstract] [Full Text] [Related]

  • 14. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K, Uemura H, Takeda M, Sekiguchi Y, Ogawa K, Hosaka M.
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [Abstract] [Full Text] [Related]

  • 15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 16. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
    Sato N, Kotake T, Masai M, Sakai S, Ito H.
    Hinyokika Kiyo; 2000 Jan 01; 46(1):1-7. PubMed ID: 10723656
    [Abstract] [Full Text] [Related]

  • 17. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM.
    J Urol; 2005 Mar 01; 173(3):784-9. PubMed ID: 15711270
    [Abstract] [Full Text] [Related]

  • 18. [Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma].
    Sumi S, Umeda H, Yano M, Koga F, Arai K, Imai T, Hosoya Y, Maeda S, Honda M, Suzuki T, Yoshida K.
    Hinyokika Kiyo; 1996 Dec 01; 42(12):937-41. PubMed ID: 9013228
    [Abstract] [Full Text] [Related]

  • 19. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 20. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K, Yamanaka H, Ito K, Yoshinaka R, Uchida S, Yokokawa K.
    Hinyokika Kiyo; 2002 Dec 01; 48(12):771-9. PubMed ID: 12613015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.